INTRODUCTION
The Central Government’s new policy to restrict the profits made by those producing life-saving medications will bring about good news for the numerous cancer patients whose conditions will become more bearable. The policy came into effect right after the Supreme Court of India stated in its ruling that the need for affordable medicines in medical emergencies is covered by the right to life guaranteed by Article 21 of the Constitution of India. The imposition of the margin limit is intended to lower the prevailing price of important cancer medication to a point that every person can afford to take the required medicine.
BACKGROUND
The high price of cancer treatment in India has raised concern for a while now, often causing families to be in debt or poverty. A Public Interest Litigation (PIL) has recently been filed in the Supreme Court that has raised awareness of the large gap between the manufacturing price of cancer medicines and the retail price of medication. The petitioners claim that the unregulated margins allowed hospitals and drug distributors to charge huge markups and that this affects patients ability to get critical medical care.
In light of the situation, the Supreme Court instructed the Union Health Ministry and the National Pharmaceutical Pricing Authority (NPPA) to devise an effective scheme to regulate these prices. The Court asserted that although pharmaceutical companies are entitled to make profits in order to finance R&D, their economic interests cannot undermine the right of the people to receive affordable medical treatment. Following the issued orders, the central government applied the Trade Margin Rationalisation (TMR) method outlined in the Drugs (Prices Control) Order (DPCO), 2013.
KEY POINTS
- The central government has announced that it will impose a cap of 30% on the trade margins of important anti-cancer drugs, which will lead to reduced retail prices.
- The Supreme Court provided crucial assistance for this change of policy by reminding the State of its constitutional responsibility to provide accessible healthcare.
- The regulation regarding drug prices will be implemented by the National Pharmaceutical Pricing Authority (NPPA), and manufacturers will have to change their Maximum Retail Price (MRP) for anti-cancer drugs.
- The judgment sends out the message that the hospitals and the sellers can no longer exploit the patients who are in difficult situations.
- The Supreme Court also suggested that it is high time for the government to continue reviewing and updating the National List of Essential Medicines (NLEM).
- The court pointed out that while the intellectual property rights and the commercial interest of the pharma industry are indeed important, they should be balanced against the necessity of public health.
ANALYSIS
The outcome is a remarkable form of judicial activism combined with executive action aimed at protecting public health. Trade Margin Rationalisation has become a useful weapon in the field of law and economics; instead of imposing limits on the maximum price of the medicine, which can lead to underproduction, it imposes restrictions on margins from the point at which drugs are sold up to the end consumer.
From a legal perspective, the intervention of the Supreme Court helps reinforce the concept that the Right to Life refers not only to mere existence but also to the right to lead a healthy life with the access to requisite healthcare services. The Court was able to connect the constitutional requirements with the state regulation of prices by bringing the government to account for the prices for drugs. Pharmaceutical companies usually argue that high prices are needed in order to recoup high costs for Research and Development, but the position made by the judiciary is very clear in relation to the fact that such costs must not be transferred fully to patients suffering from serious illnesses.
CONCLUSION
The Centre’s move to set a maximum of 30% margin for all cancer drugs is a landmark victory for the rights of patients and the field of public health in India, thanks to the firm orders of the Supreme Court. By putting an end to unethical profiteering in the pharmaceutical supply chain, the government and the judiciary have worked together to turn the product into a must-have good.
“PRIME LEGAL is a National Award-winning law firm with over two decades of experience across diverse legal sectors. We are dedicated to setting the standard for legal excellence in civil, criminal, and family law.”
WRITTEN BY: SWETHA DUTTA
